Document Detail


A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury.
MedLine Citation:
PMID:  17901087     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Previous studies have shown that omega-3 polyunsaturated fatty acids such as alpha-linolenic acid and docosahexaenoic acid (DHA) are neuroprotective in models of spinal cord injury (SCI) in rodents. However, the mechanism of action underlying these effects has not been elucidated, and the optimum treatment regime remains to be defined. We have therefore carried out a detailed analysis of the effects of DHA in adult rats subject to thoracic compression SCI. Saline or DHA (250 nmol/kg) was administered intravenously (i.v.) 30 min after compression. After injury, the saline group received a standard control diet for 1 or 6 weeks, whereas DHA-injected animals received either a control or a DHA-enriched diet (400 mg/kg/day) for 1 or 6 weeks. Other groups received a DHA-enriched diet only for 1 week following injury, or received acute DHA (250 nmol/kg; i.v.) treatment delayed up to 3 h after injury. We also assessed oxidative stress and the inflammatory reaction at the injury site, neuronal and oligodendrocyte survival and axonal damage and the locomotor recovery. At 24 h, lipid peroxidation, protein oxidation, RNA/DNA oxidation and the induction of cyclooxygenase-2 were all significantly reduced by i.v. DHA administration. At 1 week and 6 weeks, macrophage recruitment was reduced and neuronal and oligodendrocyte survival was substantially increased. Axonal injury was reduced at 6 weeks. Locomotor recovery was improved from day 4, and sustained up to 6 weeks. Rats treated with a DHA-enriched diet in addition to the acute DHA injection were not significantly different from the acute DHA-treated animals at 1 week, but at 6 weeks showed additional improvements in both functional and histological outcomes. DHA treatment was ineffective if the acute injection was delayed until 3 h post-injury, or if the DHA was administered for 1 week solely by diet. Our results in a clinically relevant model of SCI show that significant neuroprotection can be obtained by combining an initial acute i.v. injection of DHA with a sustained dietary supplementation. Given that the safety and tolerability of preparations enriched in omega-3 fatty acids is already well-documented, such a combined DHA treatment regime deserves consideration as a very promising approach to SCI management.
Authors:
W L Huang; V R King; O E Curran; S C Dyall; R E Ward; N Lal; J V Priestley; A T Michael-Titus
Related Documents :
18454337 - Low n-6:n-3 fatty acid ratio, with fish- or flaxseed oil, in a high fat diet improves p...
17876197 - Mediterranean diet and n-3 fatty acids in the prevention and treatment of cardiovascula...
9920517 - Comparison of the effects of two low fat diets with different alpha-linolenic:linoleic ...
19776627 - Effect of the ppar-alpha l162v polymorphism on the cardiovascular disease risk factor i...
9710767 - Performance, ruminal fermentation, and site of starch digestion in early lactation cows...
987167 - Arsenic trioxide absorption and excretion in industry.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-09-27
Journal Detail:
Title:  Brain : a journal of neurology     Volume:  130     ISSN:  1460-2156     ISO Abbreviation:  Brain     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-24     Completed Date:  2007-12-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372537     Medline TA:  Brain     Country:  England    
Other Details:
Languages:  eng     Pagination:  3004-19     Citation Subset:  AIM; IM    
Affiliation:
Neuroscience Centre, Institute of Cell & Molecular Science, Queen Mary University of London, UK. w.huang@qmul.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Axons / pathology
Cell Survival
Combined Modality Therapy
Cyclooxygenase 2 / analysis
Dietary Supplements
Docosahexaenoic Acids / administration & dosage*,  therapeutic use
Female
Immunohistochemistry
Injections, Intravenous
Lipid Peroxidation
Models, Animal
Neurons / pathology
Neuroprotective Agents / administration & dosage*,  therapeutic use
Oligodendroglia / pathology
Oxidation-Reduction
Oxidative Stress
Rats
Rats, Sprague-Dawley
Recovery of Function
Spinal Cord Compression
Spinal Cord Injuries / drug therapy*,  metabolism,  pathology
Chemical
Reg. No./Substance:
0/Neuroprotective Agents; 25167-62-8/Docosahexaenoic Acids; EC 1.14.99.1/Cyclooxygenase 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sexually transmitted infections among UK street-based sex workers.
Next Document:  Septic arthritis in Iceland 1990-2002: increasing incidence due to iatrogenic infections.